CacheTech Inc. Buys 4,191 Shares of Pfizer Inc. (NYSE:PFE)

CacheTech Inc. increased its stake in Pfizer Inc. (NYSE:PFE) by 22.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,976 shares of the biopharmaceutical company’s stock after buying an additional 4,191 shares during the period. CacheTech Inc.’s holdings in Pfizer were worth $610,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Retirement Wealth Solutions LLC purchased a new stake in Pfizer in the fourth quarter worth $26,000. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer in the 4th quarter worth about $26,000. Kohmann Bosshard Financial Services LLC bought a new position in shares of Pfizer in the 4th quarter worth about $28,000. Noble Wealth Management PBC purchased a new position in Pfizer during the 4th quarter valued at about $31,000. Finally, Curio Wealth LLC bought a new stake in Pfizer during the fourth quarter worth about $32,000. 68.36% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.06% of the company’s stock.

Pfizer Stock Up 0.9 %

Pfizer stock opened at $22.10 on Tuesday. The stock has a market cap of $125.34 billion, a PE ratio of 15.67, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a fifty day moving average of $25.16 and a 200 day moving average of $26.33. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s quarterly revenue was up 24.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.10 EPS. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on PFE. Citigroup reiterated a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Truist Financial cut their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. UBS Group dropped their price target on shares of Pfizer from $28.00 to $24.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 8th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Finally, Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $31.07.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.